PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Epigenome
/ genetics
Epstein-Barr Virus Infections
/ complications
Female
Gene Expression Regulation, Neoplastic
/ genetics
Genome, Human
/ genetics
Herpesvirus 4, Human
/ pathogenicity
Humans
Interferon Regulatory Factor-3
/ genetics
Interferon-gamma
/ genetics
Lymphocytes, Tumor-Infiltrating
/ metabolism
Male
Microsatellite Instability
Middle Aged
Stomach Neoplasms
/ complications
Tumor Microenvironment
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 01 2021
21 01 2021
Historique:
received:
04
11
2020
accepted:
04
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (-) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3.
Identifiants
pubmed: 33479394
doi: 10.1038/s41598-021-81667-w
pii: 10.1038/s41598-021-81667-w
pmc: PMC7820576
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
IFNG protein, human
0
IRF3 protein, human
0
Interferon Regulatory Factor-3
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1982Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K08652
Organisme : Japan Society for the Promotion of Science
ID : 18K08652
Organisme : Japan Society for the Promotion of Science
ID : 19K09099
Références
Wiley Interdiscip Rev Syst Biol Med. 2020 Nov;12(6):e1489
pubmed: 32307915
Carcinogenesis. 2020 Nov 16;:
pubmed: 33196828
Gastric Cancer. 2020 Jul;23(4):565-578
pubmed: 32468420
Cancer Lett. 2014 Apr 28;346(1):122-8
pubmed: 24368188
Carcinogenesis. 2017 Oct 26;38(11):1084-1091
pubmed: 28968686
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Res. 2012 Jul 15;72(14):3445-50
pubmed: 22761333
Clin Cancer Res. 2017 Mar 1;23(5):1220-1226
pubmed: 27620277
Cell Immunol. 2016 Dec;310:141-149
pubmed: 27641636
Cancer Sci. 2018 Jan;109(1):43-53
pubmed: 29034543
Microbes Infect. 2015 Jun;17(6):426-39
pubmed: 25777301
Sci Rep. 2017 Dec 19;7(1):17810
pubmed: 29259270
PLoS One. 2017 Apr 20;12(4):e0176045
pubmed: 28426752
Leukemia. 2019 Jan;33(1):132-147
pubmed: 29946193
Sci Rep. 2019 May 1;9(1):6769
pubmed: 31043675
Gastric Cancer. 2021 Jan;24(1):60-71
pubmed: 32506298
Gastroenterology. 2015 Jan;148(1):137-147.e9
pubmed: 25254613
Cancer Res. 2011 Dec 1;71(23):7187-97
pubmed: 21990320
Int J Oncol. 2015 Apr;46(4):1421-34
pubmed: 25633561
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Cancer Res. 2019 Jun 1;79(11):2909-2922
pubmed: 30737234
Gastric Cancer. 2020 Nov;23(6):961-973
pubmed: 32367440
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Gastric Cancer. 2020 May;23(3):510-519
pubmed: 31863227
J Exp Med. 2009 Sep 28;206(10):2091-9
pubmed: 19720839
Genes Chromosomes Cancer. 2016 Aug;55(8):626-39
pubmed: 27106868
BMC Med Genomics. 2017 Dec 06;10(1):74
pubmed: 29212506
Microorganisms. 2019 Jun 24;7(6):
pubmed: 31238570
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Int Immunopharmacol. 2017 Sep;50:121-129
pubmed: 28651122
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052